COX5A

COX5A is a nuclear-encoded structural subunit of mitochondrial respiratory chain complex IV (cytochrome c oxidase) required for complex IV biogenesis and catalytic activity (PMID:28247525). A pathogenic variant within the COX5A/COX4 interface domain reduces complex IV enzymatic activity and protein levels, causes accumulation of the monomeric COX1 assembly intermediate, and disrupts complex IV assembly, with lentiviral complementation and copper supplementation rescuing the deficiency; a second biallelic missense variant independently confirms that loss-of-function in COX5A causes mitochondrial disease with complex IV deficiency (PMID:28247525, PMID:35246835). Consistent with this catalytic role, conditions that lower COX5A — promoter hypermethylation, miR-204 targeting, or CLPP-driven misfolding — reduce complex IV activity, ATP content, and mitochondrial membrane potential while elevating ROS, and these are reversed by restoring COX5A expression (PMID:25436770, PMID:37007963, PMID:32758616). Across cardiac, vascular, neuronal, and cancer contexts, COX5A acts upstream of growth and survival signaling: its overexpression restores cytochrome c oxidase activity and ATP and activates PI3K/Akt signaling to support cardiomyocyte protection, attenuate vascular neointima formation, and drive gastric cancer proliferation and invasion (PMID:37373547, PMID:36924093, PMID:41184196), and it activates BDNF/ERK1/2 signaling to enhance hippocampal synaptic plasticity and spatial memory (PMID:32754029). COX5A-dependent mitochondrial ROS generation also functions as a signaling output, driving M2 macrophage polarization in IL-13-stimulated nasal epithelium (PMID:41842984).

1. 2017 High

   Established that COX5A is a structural subunit essential for complex IV biogenesis and that a human variant at the COX5A/COX4 interface causes complex IV deficiency, defining its disease-causing mechanism.

   Evidence Patient fibroblast enzymatic and protein assays, lentiviral complementation, assembly-intermediate detection, and copper supplementation rescue

   PMID:28247525

   Open questions at the time

   • No high-resolution structure of the human COX5A/COX4 interface within assembled complex IV
   • Mechanism by which copper supplementation partially rescues activity not defined
2. 2022 Medium

   Confirmed that biallelic loss-of-function variants in COX5A cause mitochondrial disease, generalizing the genotype-phenotype link beyond a single family.

   Evidence Clinical exome sequencing with COX5A western blot and COX enzymatic assay in patient cells

   PMID:35246835

   Open questions at the time

   • Single lab corroboration
   • No functional rescue performed for this variant
3. 2014 Medium

   Showed that COX5A expression is epigenetically regulated and that its loss is sufficient to impair complex IV activity and ATP production, linking metabolic stress to COX5A silencing.

   Evidence Promoter methylation sequencing, expression analysis, complex IV/ATP assays, and 5-aza-deoxycytidine demethylation rescue in high-fat-diet rat muscle and palmitate-treated myotubes

   PMID:25436770

   Open questions at the time

   • Rodent/cell model only
   • Transcription factors mediating methylation-dependent silencing not identified
4. 2020 Medium

   Placed COX5A upstream of BDNF/ERK1/2 signaling in neuronal function, indicating a signaling role beyond bioenergetics in cognition.

   Evidence COX5A transgenic and BDNF-knockdown mice with spatial memory, LTP, dendritic morphology, and pathway western blots

   PMID:32754029

   Open questions at the time

   • Molecular link between mitochondrial COX5A and BDNF transcription unresolved
   • Single lab
5. 2020 Low

   Identified TPI as a candidate COX5A interaction partner and a neuroprotective effector after ischemic stress.

   Evidence HSV-mediated COX5A overexpression in OGD neurons, computational interaction prediction, and western blot validation

   PMID:32349668

   Open questions at the time

   • TPI interaction shown by WB only after computational prediction, no direct binding assay
   • No reciprocal validation
6. 2020 Medium

   Demonstrated that COX5A is a direct miR-204 target and that its loss in ER+ breast cancer suppresses proliferation, EMT, and ERα, connecting COX5A regulation to oncogenic phenotypes.

   Evidence miR-204 targeting, COX5A siRNA, cell cycle, EMT marker, ATP, and ROS analyses in ER+ breast cancer cells

   PMID:32758616

   Open questions at the time

   • Mechanism linking COX5A to ERα expression undefined
   • Single lab
7. 2023 Medium

   Established COX5A as a protective factor upstream of PI3K/Akt in doxorubicin cardiotoxicity, restoring complex IV activity, ATP, and mitochondrial morphology.

   Evidence AAV9/lentiviral COX5A overexpression in mice and H9c2 cells with COX/ATP assays, TEM, and PI3K inhibitor rescue

   PMID:37373547

   Open questions at the time

   • Direct molecular link from complex IV/ATP to Akt phosphorylation not defined
   • Single lab
8. 2023 Medium

   Showed COX5A overexpression restores mitochondrial function in vascular smooth muscle cells and limits neointima formation, extending its protective role to vascular injury.

   Evidence COX5A overexpression/knockdown in HA-VSMCs with Seahorse, COX/ATP/ROS assays, proliferation/migration assays, and rat balloon injury model

   PMID:36924093

   Open questions at the time

   • Signaling pathway downstream of restored mitochondrial function in VSMCs not delineated
   • Single lab
9. 2023 Medium

   Defined COX5A as a target of CLPP-dependent proteostasis whose misfolding/aggregation drives complex IV loss, ROS, and intrinsic apoptosis.

   Evidence CLPP inhibition plus COX5A overexpression/knockdown in human ovarian granulosa cells with complex IV, ROS, membrane potential, and apoptosis assays

   PMID:37007963

   Open questions at the time

   • Whether CLPP directly processes COX5A not shown
   • Single lab
10. 2024 Low

    Proposed a non-canonical role for COX5A in oxidative stress detoxification via YAP1 regulation through alternative translation initiation in yeast.

    Evidence Yeast deletion strains, H2O2 sensitivity, YAP1 expression, epistasis, and translation initiation reporters

    PMID:38416461

    Open questions at the time

    • Yeast model only, not validated in mammalian cells
    • Mechanism of alternative translation initiation regulation unresolved
11. 2025 Medium

    Showed COX5A-driven OXPHOS and ATP activate PI3K/Akt to promote gastric cancer growth, establishing a pro-tumorigenic bioenergetic-signaling axis.

    Evidence COX5A overexpression/silencing in gastric cancer lines with JC-1, ATP assays, PI3K/Akt western blot, inhibitor rescue, and xenografts

    PMID:41184196

    Open questions at the time

    • Direct molecular coupling of ATP levels to PI3K/Akt activation undefined
    • Single lab
12. 2026 Medium

    Demonstrated that COX5A-dependent mitochondrial ROS in nasal epithelium drives M2 macrophage polarization, framing COX5A output as an inflammatory signaling source.

    Evidence COX5A siRNA in IL-13-stimulated epithelial cells with ROS scavenger controls, macrophage polarization flow cytometry, and murine nasal polyp model

    PMID:41842984

    Open questions at the time

    • Soluble or contact mediators of epithelium-to-macrophage signaling not identified
    • Single lab

• How COX5A bioenergetic output is mechanistically transduced into discrete downstream signaling programs (PI3K/Akt, BDNF/ERK1/2, ROS-driven inflammation) across tissues remains unresolved.
• No direct molecular link established between complex IV activity/ATP/ROS and the activated kinase cascades
• Whether signaling effects are tissue-specific or generalizable is unknown